<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               17	PATIENT COUNSELING INFORMATION<BR>               <BR>                  <BR>                     See FDA-approved Patient labeling (Medication Guide)<BR>                  <BR>                  <BR>                     Embryo-Fetal Toxicity <BR>                     <BR>Advise patients that REVLIMID is contraindicated in pregnancy [see Contraindicatons (4.1)]. REVLIMID is a thalidomide analog and can cause serious birth defects or death to a developing baby. [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1)].  <BR>                            	<BR>                  <BR><BR>                  <BR>                     Advise females of reproductive potential that they must avoid pregnancy while taking REVLIMID and for at least 4 weeks after completing therapy.<BR>                     Initiate REVLIMID treatment in females of reproductive potential only following a negative pregnancy test.  <BR>                     Advise females of reproductive potential of the importance of monthly pregnancy tests and the need to use two different forms of contraception including at least one highly effective form simultaneously during REVLIMID therapy, during dose interruption and for 4 weeks after she has completely finished taking REVLIMID.  Highly effective forms of contraception other than tubal ligation include IUD and hormonal (birth control pills, injections, patch or implants) and a partner’s vasectomy.  Additional effective contraceptive methods include latex or synthetic condom, diaphragm and cervical cap.  <BR>                     Instruct patient to immediately stop taking REVLIMID and contact her doctor if she becomes pregnant while taking this drug, if she misses her menstrual period, or experiences unusual menstrual bleeding, if she stops taking birth control, or if she thinks FOR ANY REASON that she may be pregnant. <BR>                     Advise patient that if her doctor is not available, she can call 1-888-668-2528 for information on emergency contraception [see Warnings and Precautions (5.1) and Use in Specific Populations (8.6)].  <BR>                     Advise males to always use a latex or synthetic condom during any sexual contact with females of reproductive potential while taking REVLIMID and for up to 28 days after discontinuing REVLIMID, even if they have undergone a successful vasectomy.  <BR>                     Advise male patients taking REVLIMID that they must not donate sperm [see Warnings and Precautions (5.1) and Use in Specific Populations (8.6)].  <BR>                     All patients must be instructed  to not  donate blood while taking REVLIMID, during dose interruptions and for 1 month following discontinuation of REVLIMID [see Warnings and Precautions (5.1) and Use in Specific Populations (8.6)].    <BR>                  <BR>                  <BR>                     REVLIMID REMS™ program<BR>                     <BR>Because of the risk of embryo-fetal toxicity, REVLIMID is only available through a restricted program called the REVLIMID REMS™ program<BR>                      (formerly known as the “RevAssist®” program)<BR>                     [see Warnings and Precautions (5.2)].<BR>                            	<BR>                  <BR>                     Patients must sign a Patient-Prescriber agreement form and comply with the requirements to receive REVLIMID. In particular, females of reproductive potential must comply with the pregnancy testing, contraception requirements and participate in monthly telephone surveys. Males must comply with the contraception requirements [see Use in Specific Populations (8.6)].<BR>                     REVLIMID is available only from pharmacies that are certified in REVLIMID REMS™ program. Provide patients with the telephone number and website for information on how to obtain the product<BR>                  <BR>                  <BR>                     Hematologic Toxicity<BR>                  <BR>                  REVLIMID is associated with significant neutropenia and thrombocytopenia [See Boxed Warnings and Warnings and Precautions (5.3)]<BR>                  <BR>                  <BR>                     Venous Thromboembolism<BR>                  <BR>                  REVLIMID/dexamethasone has demonstrated significant increased risk of DVT and PE in patients with multiple myeloma [See Boxed Warnings and Warnings and Precautions (5.4)]<BR>                  <BR>                  <BR>                     Allergic Reactions<BR>                  <BR>                  Inform patients of the potential for allergic reactions including hypersensitivity, angioedema, Stevens Johnsons Syndrome, or toxic epidermal necrolysis if they had such a reaction to THALOMID and report symptoms associated with these events to their healthcare provider for evaluation.<BR>                  <BR>                     Tumor Lysis Syndrome<BR>                  <BR>                  Inform patients of the potential risk of tumor lysis syndrome and report any signs and symptoms associated with this event to their healthcare provider for evaluation. <BR>                  <BR>                     Tumor Flare Reaction<BR>                  <BR>                  Inform patients of the potential risk of tumor flare reaction and report any signs and symptoms associated with this event to their healthcare provider for evaluation. <BR>                  <BR>                     Hepatotoxicity<BR>                  <BR>                  Inform patients of the risk of hepatotoxicity and report any signs and symptoms associated with this event to their healthcare provider for evaluation. <BR>                  <BR>                     Secondary Primary Malignancies <BR>                  <BR>                  <BR>                     Inform patients of the potential risk of developing second primary malignancies during treatment with REVLIMID.<BR>                  <BR>                  <BR>                     Dosing Instructions<BR>                  <BR>                  Inform patients to take REVLIMID once daily at about the same time each day, either with or without food. The capsules should not be opened, broken, or chewed. REVLIMID should be swallowed whole with water.<BR>                  Instruct patients that if they miss a dose of REVLIMID, they may still take it up to 12 hours after the time they would normally take it. If more than 12 hours have elapsed, they should be instructed to skip the dose for that day. The next day, they should take REVLIMID at the usual time. Warn patients to not take 2 doses to make up for the one that they missed.<BR>                  Manufactured for: 	Celgene Corporation<BR>                            		<BR>                            Summit, NJ 07901<BR>                            	<BR>                  REVLIMID®, RevAssist®, and THALOMID® are registered trademarks of Celgene Corporation.<BR>                  U.S. Pat. Nos. 5,635,517; 6,045,501; 6,281,230; 6,315,720; 6,555,554; 6,561,976; 6,561,977; 6,755,784; 6,908,432; 7,119,106; 7,189,740; 7,465,800; 7,855,217; 7,968,569<BR>                  ©2005-2013 Celgene Corporation, All Rights Reserved.<BR>                  RevPlyPI.015L/MG.015L   02/13<BR>               <BR>               <BR>            <BR>         </P></DIV></HTML>